BiotechTube

Selumetinib + Placebo

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 1

Conditions

Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative

Trial Timeline

Aug 31, 2023 → Jun 30, 2026

NCT ID
NCT05825365

About Selumetinib + Placebo

Selumetinib + Placebo is a phase 2 stage product being developed by AstraZeneca for Neurofibromatosis Type 1. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05825365. Target conditions include Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05825365Phase 2Withdrawn

Competing Products

20 competing products in Neurofibromatosis Type 1

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60
BinimetinibPacific BiosciencesPhase 2
44

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85